PreClara Ratio: On-Demand Education

Enhancing preeclampsia care with the sFlt-1/PlGF ratio: Implementation and clinical use cases

Webinar June 2025 (1 hour)

This webinar explores the clinical application of the sFlt-1/PlGF ratio as a prognostic biomarker for preeclampsia with severe features. Dr. Woodham will review clinical evidence demonstrating its value in risk stratification and guiding management strategies, illustrated by specific use cases. 

Speakers

Padmashree Chaudhury Woodham, MD

Professor of Maternal-Fetal Medicine

MFM Fellowship Program Director

Medical College of Georgia

Learning objectives

  • Discuss implementation of the sFlt-1/PlGF biomarker test in clinical practice.
  • Understand the significant benefits of the sFlt-1/PlGF biomarker test in preeclampsia management, as supported by real-world evidence.
  • Explore the value of the sFlt-1/PlGF test in assessing the risk of developing severe preeclampsia within a two-week timeframe, and how it can effectively contribute to safely prolonging pregnancies.
  • Demonstrate the biomarker test’s ability to optimize treatment decisions and provide more precise and effective management of preeclampsia, particularly in situations of uncertainty or non-specific laboratory results.

Fill out the form to download the full case study.

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

 

© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.